Tirzepatide

Released: January 15, 2026Last reviewed: October 15, 2026

Dual GLP-1/GIP receptor agonist. Brand names: Mounjaro (T2D), Zepbound (chronic weight management; OSA in adults with obesity).

By Eli LillyUpdated 2026-05-25

Researched By

Dr. Parmis

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Tirzepatide overview

Dual GLP-1/GIP receptor agonist. Brand names: Mounjaro (T2D), Zepbound (chronic weight management; OSA in adults with obesity).

Manufacturer

Eli Lilly

FDA status

FDA-approved

Tirzepatide